Background Second hematologic cancers in patients with chronic lymphocytic leukemia/
Introduction
Chronic lymphocytic leukemia (CLL) is among the most common types of cancer. The incidence of CLL is increasing at a rate of 2-4% annually since 1992, after tripling from 1958 to 1992. 1 
CLL is included in the non-Hodgkin lymphoma (NHL)
family and is classified as a low-grade lymphoproliferative malignancy with clonal expansion of B cells. 2 Patients with CLL have been shown to be at increased risk for secondary cancers. [3] [4] [5] [6] [7] [8] [9] Cutaneous neoplasms, such as squamous cell carcinoma, basal cell carcinoma, malignant melanoma, and other rare cutaneous cancers, occur more frequently and aggressively in patients with CLL, possibly due to an altered immune system. 7, [10] [11] [12] [13] [14] Cutaneous lymphomas embody a heterogeneous group of T-and B-cell lymphomas and represent 3.9% of all NHLs. 15 In the United States, the incidence of cutaneous T-cell lymphoma (CTCL) has increased since 1973 from 6.4 to 9.6 cases per million people. 16 CTCLs include the more common mycosis fungoides and S ezary syndrome, 17 as well as other rare T-cell lymphomas such as CD30-positive lymphoproliferative disorders, subcutaneous panniculitis-like T-cell lymphoma, and peripheral T-cell lymphoma. Mycosis fungoides is a generally more indolent form of CTCL, characterized as an epidermotropic proliferation of T lymphocytes, and makes up the majority of cutaneous lymphomas. S ezary syndrome is an aggressive and leukemic form of CTCL defined by the triad of erythroderma, generalized lymphadenopathy, and neoplastic T cells in the skin, lymph nodes, and peripheral blood. 18, 19 An association between CTCL and CLL has been described in prior reports. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] However, the incidence of CTCL occurring in patients with CLL has not been investigated in a large population-based study. Because the 
Statistical analysis
Patients with CLL and NHL were analyzed separately. Within each analysis, patients were excluded if their CTCL diagnosis came before or up to 1 month after that of CLL or NHL. Followup duration was calculated from the date of CLL or NHL diagnosis until CTCL diagnosis, last follow-up, or death, whichever occurred first. Sex-and age group-specific incidence density estimates were derived for each analysis using the number of patients with the incident diagnosis (observed) relative to total person-years of observation. Rates were expressed as incidence per 1,000,000 person-years, 35 and primary cutaneous CD30+ T-cell lymphoma in 5. CLL, chronic lymphocytic leukemia; CTCL, cutaneous T-cell lymphoma; NHL, non-Hodgkin lymphoma; PY, person-years; SIR, standardized incidence ratio. CTCL, cutaneous T-cell lymphoma; NHL, non-Hodgkin lymphoma; NOS, not otherwise specified; Pt, patient. statistical significance (P = 0.06). Among males with CLL, the risk of CTCL was significantly higher than expected in the general population (SIR, 3.0; 95% CI, 1.4-5.5; P < 0.001). Among females with CLL, the observed risk of CTCL was not higher than expected (SIR, 1.5; 95% CI, 0.2-5.5; P = 0.74). Among patients with NHL, the incidence of CTCL per 1,000,000 person-years was similar in men (97.9; 95% CI, 62.0-146.9) and women (92.0; 95% CI, 56.2-142.1; P = 0.84). The risk of CTCL among males with NHL (SIR, 3.7; 95% CI, 2.3-5.5) and among females with NHL (SIR, 5.9; 95% CI, 3.6-9.1) was significantly higher than expected in the general population (both P < 0.001).
Discussion
To our knowledge, this is the first large population-based study investigating the incidence of CTCL in patients with CLL and NHL. We found that the risk of CTCL in men with CLL is significantly greater than in the general population. However, the risk of CTCL was not increased in women with CLL. In both men and women with NHL, the risk of CTCL was greater than in the general population.
Although the proliferation of two separate lymphocytic lineages is rare, this study shows that patients with CLL or NHL are at increased risk for CTCL development. Several hypotheses have been presented to explain this phenomenon, such as that these cells (i) come from a common stem cell progenitor or genetic events; (ii) occur secondary to carcinogens, viruses, cytokines from T-cell or B-cell clones, or treatment of the preexisting lymphoproliferative disease; or (iii) occur by coincidence. 33 CLL/NHL is also associated with an altered immune system, which can potentially contribute to the development of secondary malignancy. 7 The development of CTCL in patients with CLL appears to be multifaceted.
This study aligns with reports that have described CTCL occurring in patients with CLL. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Among these reports, the largest series consisted of 14 patients, of which 8 had concurrent diagnoses of CLL and CTCL, 5 patients had CLL diagnosed first, and 1 patient had CTCL diagnosed first. 33 In that study, the authors noted that patients with CLL and concurrent CTCL appeared to have worse overall median survival (12 months) than patients with a prior history of CLL and later diagnosis of CTCL (47 months). 33 Although the mechanism is unclear, the behavior of CTCL in patients with CLL may be more aggressive because of the immunosuppression associated with CLL. Management of CTCL may need to be adjusted in the setting of CLL to account for this consideration.
Of interest, in the current study, the female patients with CLL did not have an increased risk of CTCL. In contrast, the incidence of CTCL in women with NHL who were younger than 50 years was quite high; Table 3 shows the sites and dates of development of CTCL among these five women. The reason for the different incidence of CTCL in women of different ages is unknown. Further research will be needed to elucidate these differences.
Limitations of this study include those inherent to registry database studies, such as selection bias, coding of events not being primarily for research purposes, and potential inputting errors in the data. 36 The strengths of the SEER database itself include the wealth of data that can be used to categorize cancers and the ability to perform epidemiologic analyses on cancers with a large and comprehensive database. 37 In conclusion, CLL/NHL is among the most common types of cancer, and the incidence is increasing. Patients with CLL/ NHL are in an immunocompromised state. Although patients with CLL/NHL are more commonly known to be at higher risk for cutaneous neoplasms such as squamous cell carcinoma, basal cell carcinoma, and melanoma, CLL/NHL is less commonly known to be associated with CTCL. This study confirms that those with CLL/NHL are at higher risk for CTCL. Providers should be aware of this association because CTCL can be a source of morbidity in this immunocompromised population. Increased awareness of this association by physicians and other healthcare providers could afford earlier recognition and more prompt management of CTCL in patients with CLL/ NHL.
